Related Experiment Videos
Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease
P Sestini1, E Renzoni, S Robinson
1Institute of Respiratory Diseases, University of Siena, Viale Bracci 3, 53100, Siena, Italy. sestini@unisi.it
The Cochrane Database of Systematic Reviews
|January 10, 2003
Summary
Regular use of short-acting beta-2 agonists in stable Chronic Obstructive Pulmonary Disease (COPD) improves lung function and reduces breathlessness. Patients show a strong preference for these bronchodilators over placebo, with fewer dropouts, though long-term side effects require further study.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive airflow limitation.
- Short-acting beta-2 bronchodilators offer symptomatic improvement despite limited reversibility in COPD patients.
- These medications are integral to managing both stable COPD and acute exacerbations.
Purpose of the Study:
- To evaluate the clinical effectiveness of regular short-acting beta-2 agonist treatment in stable COPD patients.
- To assess the adverse effects associated with this regular bronchodilator therapy.
Main Methods:
- Conducted a systematic search of the Cochrane Airways Group database and relevant literature.
- Included randomized controlled trials (RCTs) of at least one week comparing short-acting beta-2 agonists with placebo in stable COPD.
- Employed independent data extraction and quality assessment, with author contact for missing information.
Main Results:
- Thirteen high-quality crossover RCTs demonstrated significant improvements in FEV1, FVC, and PEFR compared to placebo.
- Patients reported decreased breathlessness and preferred beta-2 agonists over placebo, with reduced treatment failure rates.
- One study indicated significant improvements in dyspnea and fatigue scores; no serious side effects were reported, but study limitations precluded long-term safety assessment.
Conclusions:
- Regular short-acting beta-2 agonist use in stable COPD enhances lung function and alleviates breathlessness.
- Patient preference and adherence are significantly higher with beta-2 agonists compared to placebo.
- While beneficial, further large-scale, long-term studies are necessary to fully understand side effects and impact on disease progression. Newer long-acting bronchodilators may offer practical advantages, but current evidence supports the utility of these established, cost-effective agents.